Copy to clipboard 
The STS Group acquired Accentus Medical, developer of surface treatments for medical implants and devices. Headquartered in the UK, the Accentus supplies the majority of its products to international customers. Its proprietary coatings and surface modification technologies have delivered clinically proven outcomes over more than 20 years, improving the performance and longevity of orthopedic implants.
“The addition of Accentus Medical into the STS Group marks an important milestone in our growth strategy”, said Nathan Davies, CEO of STS Group. “Their expertise in medical coatings, combined with a leading reputation for product quality will facilitate our expansion into the healthcare sector, allowing us to provide innovative solutions that align with industry demands for high-performance, biocompatible coatings.”
“The Accentus Medical team is excited to join the STS Group”, said Philip Agg, CTO of Accentus Medical. “The company will continue to operate under its established name while benefiting from STS Group’s global resources and infrastructure. The combined expertise and technological synergies of Accentus Medical and STS Group will drive innovation, production efficiency, and customer-focused solutions, as well as offer the opportunity to expand our global manufacturing footprint.”
Source: Accentus Medical
